Skip to main content
. 2015 Aug 11;11(4):411–434. doi: 10.1007/s11302-015-9462-7

Fig. 5.

Fig. 5

Three P2 receptor subtypes, P2X1, P2Y1 and P2Y12, are involved in ADP-induced platelet activation. Clopidogrel is a P2Y12 receptor blocker that inhibits platelet aggregation and is in highly successful use for the treatment of thrombosis and stroke. A P2Y1 receptor antagonist, MRS 2500, inhibits shape change. (Modified from [403] with permission from Elsevier.)